Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Founder operating in the Medical space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Dr. Jon Einarsson
Founder & Inventor of Lattis Surgical
Follow Dr. Jon Einarsson:
About Harvard Medical School, Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Alexander Isakov
Founder & CEO of Lattis Surgical
Follow Alexander Isakov:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Jordan Smith
Founder & Board of Directors of Lattis Surgical
Follow Jordan Smith:
About Lattis Surgical: The Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology.
Gregory Winter
Scientific Founders of Bicycle Therapeutics
Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and most of his scientific career was based there. He was Head of Division of Protein and Nucleic Acid Chemistry, succeeding Cesar Milstein and has served as both Deputy and Acting Director of the LMB. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge. Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing respectively and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies. He invented techniques to humanise rodent antibodies for use as therapeutics (1986–), working with H. Waldmann in the development of alemtuzumab/Campath-1H. Later, in competition with R. Lerner, he developed methods to make fully human antibodies (1989–) against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the US FDA. Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics. CAT was floated on the London Stock Exchange in 1997 and was responsible for the co-development of the therapeutic antibodies adalimumab/Humira and belimumab/Benlysta. CAT was acquired by AstraZeneca in 2006. Domantis developed a range of product leads based on single antibody domains and was acquired by GSK in 2006 in a private sale. Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (US) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.
Follow Gregory Winter:
About Ahren Innovation Capital, Bicycle Therapeutics, MRC Laboratory of Molecular Biology, Trinity College, Dublin: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Christian Heinis
Scientific Founders of Bicycle Therapeutics
Christian Heinis is Scientific Founders at Bicycle Therapeutics.
Follow Christian Heinis:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Nick Lydon
Scientific Founder of Blueprint Medicines
Nick Lydon, Ph.D., is a scientific founder of Blueprint Medicines. Before founding his current consulting company, Granite Biopharma, LLC, Dr. Lydon served as vice president, small molecule drug discovery at Amgen. Prior to joining Amgen, he founded and led Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, a number of which are now advancing through clinical development. Kinetix was acquired by Amgen in 2000. Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program. He and his team identified a number of protein kinase inhibitors. The most advanced drug from this program is Gleevec®, a selective Bcr-Abl inhibitor for the treatment of chronic myelogenous leukemia (CML). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant alpha, beta and gamma interferons. In 2009, Dr. Lydon was awarded the Lasker-DeBakey Award for Clinical Medical Research for his work on developing Gleevec®, converting a fatal cancer into a manageable chronic condition. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award, and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation for his contributions to the discovery and development of Gleevec®. Dr. Lydon earned a B.S. in biochemistry from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. His thesis involved research work on adenylate cyclase and cAMP dependent protein kinase. Dr. Lydon served as an advisor and member of the board of directors of Ambit BioScience from 2004 to 2009 and assisted in the development of AC220, a FLT3 kinase inhibitor in Phase 2 clinical development in relapsed/refractory acute myeloid leukemia (AML).
Follow Nick Lydon:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Sammy Khalifa
Co-Founder and CTO of Vicarious Surgical
Follow Sammy Khalifa:
About Vicarious Surgical: Vicarious Surgical improves the lives of patients and surgeons by giving access to high quality care through the use of surgical robotics.
Allen Lin
Co-Founder and CSO of Oncolinx
Follow Allen Lin:
About Harvard University, Oncolinx: Oncolinx is developing antibody-drug conjugates.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Oliver Armitage
Co-Founder & CSO of BIOS
Oliver Armitage is Co-Founder and Chief Scientific Officer at BIOS, a leading neural engineering startup. Oliver has always had a vision that the human body could be repaired or made better through augmentative technology and how that can be used to improve people’s lives. He studied for his PhD at the University of Cambridge in Bioengineering, working in the world-renowned Nanoscience Centre. He specializes in tissue interfaces and engineering to allow technology to be fused with the body. Oliver was recently named to Forbes 30 Under 30 2018.
Follow Oliver Armitage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Giulio Ruffini
President, CTO, Co-Founder of Neuroelectrics
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders, and improves overall brain health.
Raghu Kalluri
Scientific Founder of Codiak Biosciences
Raghu Kalluri is Chairman and Professor of the Department of Cancer Biology and the Director of the Metastasis Research Center at The University of Texas MD Anderson Cancer Center, where he also holds the Rebecca and Joseph Brown Endowed Chair. CPRIT funding helped bring Raghu Kalluri to Texas from Harvard Medical School in 2012. Raghu Kalluri received his Ph.D. in Biochemistry and Molecular Biology from the University of Kansas Medical Center and his M.D. degree from Brown University Medical School. He was a postdoctoral fellow and a research associate at the University of Pennsylvania Medical School and performed research in areas of immunology and organ fibrosis. In 1997, he moved to Harvard Medical School as an Assistant Professor of Medicine and as a faculty based in the Department of Medicine at the Beth Israel Deaconess Medical Center. Subsequently, Kalluri was appointed the Chief of the Division of Matrix Biology and promoted to Professor of Medicine at Harvard Medical School. He held appointments in the Department of Biological Chemistry and Molecular Pharmacology at HMS, Harvard MIT Division of Health Sciences and Technology, Harvard Stem Cell Institute and was a research fellow of the HMS Peabody Society. Kalluri has trained more than 70 postdoctoral fellows and 20 graduate students in his career. He is a fellow of American Society of Clinical Investigation and the American Association for the Advancement of Science. In addition, Kalluri serves on science and health advisory panels in the U.S. and European Union and on the editorial boards of several academic journals representing biology and medicine.
Follow Raghu Kalluri:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Jonathan Zhao
Co-Founder and Chairman of Hangzhou Just Biotherapeutics (Just China)
Asia strategy across small molecule, biologics and vaccine. He had also served as the interim head of Pfizer’s Bio-enhancement Development Unit during 2009-2010 in charge of the biosimilar and biobetter strategy development and business operation. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), PhD. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.
Follow Jonathan Zhao:
About Hangzhou Just Biotherapeutics (Just China), Transcenta: Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Glenn Robertelli
Co-Founder & Chief Operating Officer of Admetsys
Follow Glenn Robertelli:
About Admetsys: For people at diabetic risk, glucose control is at its most crucial while in hospital or surgery.
Shawn Marcell
Co-Founder, President & CEO of Torus Biosystems
Follow Shawn Marcell:
About Torus Biosystems: Torus Biosystems is a biotech startup that delivers molecular diagnostics for infectious diseases.
Mehmet Toner
Founder of Torpedo Diagnostics
Mehmet Toner is the Helen Andrus Benedict Professor of Bioengineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Health Sciences & Technology. He is internationally recognized for his research at the interface of nanotechnology, microsystems engineering, microfluidics, and applications in clinical medicine. Dr. Toner was born in Istanbul, Turkey. He obtained his undergraduate degree in mechanical engineering at the Istanbul Technical University, and his master’s degree and doctorate in Mechanical Engineering at MIT. He is the author of more than 300 original scientific and technical publications, and an inventor on more than 30 patents. Dr. Toner is a pioneer in the development of technologies to isolate extremely rare cells from blood, including circulating tumor cells. He is the founding Director of the NIH BioMicroElectroMechanical Systems Center, a nationwide center exploring the applications of microfluidics and nanotechnology in clinical medicine and life sciences. His work in cancer was awarded the Quantum grant from NIH as part of the “moon shot” program. His work has resulted in the formation of multiple companies servicing clinical diagnostics and biotechnology.
Follow Mehmet Toner:
About Massachusetts General Hospital, Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Daniel Haber
Founder of Torpedo Diagnostics
Daniel Haber is the Director of Massachusetts General Hospital (MGH) Cancer Center, the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute (HHMI). He earned his BS and MS degrees from Massachusetts Institute of Technology (MIT), and his MD and PhD from Stanford. He completed his residency in internal medicine at MGH, his clinical fellowship in oncology at Dana Farber Cancer Institute, and his postdoctoral training at MIT, before joining the MGH faculty in 1991. Dr. Haber is known for his research in cancer genetics, including the discovery of genes implicated in the pediatric kidney cancer Wilms Tumor, the prevalence of founder BRCA mutations in young women of Ashkenazi descent. In 2004, his laboratory identified specific mutations in the epidermal growth factor receptor (EGFR) gene that underlie exquisite sensitivity to targeted kinase inhibitors, a milestone in the development of precision oncology targeting genetically-identified subsets of common epithelial cancers. The MGH Cancer Center now conducts a broad range of first-in-human clinical trials of targeted anti-cancer agents. Dr. Haber’s research is currently focused on the use of circulating tumor cells (CTCs) as a non-invasive “liquid biopsy” to detect and interrogate cancer cells at different stages of treatment response and disease progression, a project for which he and his close collaborator Dr. Mehmet Toner were awarded a Stand Up To Cancer Dream Team Award. Dr. Haber is a member of the National Academy of Medicine (Institute of Medicine), the American Academy of Arts and Science (AAAS), the Association of American Physicians (AAP), and the American Society for Clinical Investigation (ASCI).
Follow Daniel Haber:
About Torpedo Diagnostics: Torpedo Diagnostics is revolutionizing cancer detection, management and cure with a proprietary technology platform .
Mosin Badkar
Co-Founder and VP of Cardiac Design Labs
Mosin Badkar is responsible for product R and D and Algorithms. His scope includes design of new products, prototyping of design and proof of concept. His scope also includes planning and tracking of new product designs, system level and various software development activities.
Follow Mosin Badkar:
About Cardiac Design Labs: Cardiac Design Labs is into designing, developing, deploying and selling intelligent devices for medical purpose.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Rajesh Devraj
CSO & Co-Founder of Disarm Therapeutics
Follow Rajesh Devraj:
About Atlas Venture, Disarm Therapeutics, Rectify Pharmaceuticals: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Nathan Rodman
CTO and Co-Founder of Perch
Nathan Rodman and Jacob Rothman founded Perch in July 2016, since which Nate has been serving as its chief technology officer.
Follow Nathan Rodman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
Derrick Rossi
Founder of Intellia Therapeutics
In 2010, Dr. Rossi discovered a groundbreaking method to reprogram skin cells into stem cells utilizing messenger molecules. His novel technique eliminated the risk of cancer posed by previous methods and sparked a push to develop cellular and molecular therapeutic products using the technologies he developed. More recently, Dr. Rossi and colleagues again innovated in the stem cell field by applying the CRISPR/Cas9 system to generate hematopoietic stem cells resistant to HIV infection. Dr. Rossi continues to study CRISPR for application in human therapeutics.
Follow Derrick Rossi:
About Convelo Therapeutics, Intellia Therapeutics, Moderna Therapeutics, Stelexis Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Rodolphe Barrangou
Co-Founder of Intellia Therapeutics
Rodolphe Barrangou is an Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University. His lab focuses on the biology and genetics of CRISPR/Cas immune systems in bacteria. He also serves on the Board of Directors of Caribou Biosciences. Rodolphe was previously a Director of Research and Development at DuPont and Danisco. While with Dansico, he was part of the team that initially established the adaptive immune function of CRISPR systems. Rodolphe received his PhD in Functional Genomics from North Carolina State University and an MBA from the University of Wisconsin, Madison.
Follow Rodolphe Barrangou:
About Intellia Therapeutics, North Carolina State University – NCSU: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Luciano Marraffini
Founder & Advisor of Intellia Therapeutics
Luciano Marraffini is an Assistant Professor of Bacteriology at Rockefeller University. Luciano’s laboratory investigates the underlying molecular mechanisms of CRISPR immunity, and seeks to employ this natural pathway to develop new technologies. He is a 2012 Rita Allen Foundation Scholar and the recipient of a 2012 NIH Director’s New Innovator Award. Luciano received his PhD from the University of Chicago where he studied bacterial pathogenesis, and completed his postdoctoral fellowship at Northwestern University.
Follow Luciano Marraffini:
About Eligo Bioscience, Intellia Therapeutics, The Rockefeller University: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Timothy A. Springer
Co-Founder of Scholar Rock
Timothy Springer is an internationally recognized leader in structural biology and immunology. With over 500 peer-reviewed publications that have received over 90,000 citations, he is one of the most highly cited scientists in any field. Timothy Springer received his Ph.D. from Harvard University in 1976, and subsequent post-doctoral training with Dr. Cesar Milstein in Cambridge, UK. Timothy Springer has been elected to the National Academy of Sciences and to the American Academy of Arts and Sciences. Among numerous awards and honors, Timothy Springer is a recipient of the Royal Society of Medicine Medal, the William B. Coley Medal from the Cancer Research Institute, and the Crafoord Prize from the Swedish Academy of Sciences. Timothy Springer’s research laid the foundation for a new class of pharmaceuticals, the selective adhesion molecule inhibitors, which include the approved drugs, alefacept, efalizumab and natalizumab. Timothy Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. LeukoSite developed therapeutics for inflammatory, autoimmune, and cancer applications, including FDA-approved Campath™.
Follow Timothy A. Springer:
About Harvard University, Institute for Protein Innovation, Moderna Therapeutics, Morphic Therapeutic, Scholar Rock: Scholar Rock is discovering and developing a new class of biologic therapies.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Wei Li
Co-Founder of Morphogen-IX
Wei Li, Co-Founder at MORPHOGEN-IX LIMITED.
Follow Wei Li:
About Morphogen-IX: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Eoin McKinney
Chief Scientific Officer & Co-Founder of PredictImmune
Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Follow Eoin McKinney:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Kenneth Smith
Co-Founder & Chief Medical Officer of PredictImmune
Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Follow Kenneth Smith:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
David Brown
Co-Founder and Chairman of the Board of Directors of Healx
David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia. David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of two charities, Antibiotic Research UK, dedicated to solving the looming problem of antibiotic resistance; and Friends of Manjushree Vidyapith School and Orphanage, a charity he co-founded in 2005 to help destitute orphans in South Tibet.
Follow David Brown:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Trey Foskett
Co-Founder and CEO of Watchmaker Genomics
Trey Foskett is the Co-Founder and CEO of Watchmaker Genomics.
Follow Trey Foskett:
About Watchmaker Genomics: Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Tony Kouzarides
Co-Founder of Storm Therapeutics
Tony Kouzarides is Founder at Chroma Therapeutics. He is Co-Founder at Abcam.
Follow Tony Kouzarides:
About Abcam, Cambridge Gravity, Chroma Therapeutics, Milner Therapeutics Institute, Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Eric Miska
Co-Founder of Storm Therapeutics
Eric is the Herchel Smith Professor of Molecular Genetics and a Senior Group Leader at the Gurdon Institute at the University of Cambridge. He has an appointment as associated faculty at the Cambridge Systems Biology Centre and the Cancer Research UK Cambridge Research Institute. Eric was an EMBO Young Investigator and is a full member of EMBO since 2012. Eric is the 2013 recipient of the Hooke Medal awarded by the British Society of Cell Biology. He joined the faculty of the Wellcome Trust Sanger Institute in Hinxton in 2014 and is a Senior Investigator of the Wellcome Trust. Eric studied mathematics, physics and biology at Heidelberg, Berlin and Mainz and holds a BA in Biochemistry from Trinity College, Dublin. He received his PhD in Pathology from the University of Cambridge, UK, in 2000, working with Professor Tony Kouzarides, and was a postdoctoral fellow in the laboratory of Nobel laureate Bob Horvitz at the Massachusetts Institute of Technology, Cambridge, MA, USA from 2000 to 2004. He started his own research group at the Gurdon Institute in 2005.
Follow Eric Miska:
About Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Bert Vogelstein
Founder of Thrive Earlier Detection
Bert Vogelstein is a pioneer in cancer genomics, Dr. Bert Vogelstein was the first scientist to elucidate the molecular basis of a common human cancer. In particular, he and his colleagues demonstrated that colorectal tumors result from the gradual accumulation of genetic alterations in specific oncogenes and tumor suppressor genes. His group’s work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future. His early work on the nature of cancer genomes was dramatically confirmed when he and Thrive co-founder Kenneth W. Kinzler, Ph.D., led a team that was able to determine the sequence of every gene in colorectal, pancreatic, brain, breast and other cancers. Bert and Ken have used this information to design a new generation of screening tests for various cancer types. In the process, they invented the fundamental technologies used to identify rare mutations in clinical samples. Bert is currently the Clayton Professor of Oncology and Pathology and co-director of the Ludwig Institute at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins University School of Medicine, and is also a Howard Hughes Medical Institute Investigator. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Inventors and has held editorial positions at Science and The New England Journal of Medicine, among others. He is the recipient of numerous awards for his ground-breaking studies on the pathogenesis of human cancer, including the 2013 Breakthrough Prize in Life Sciences, The Gairdner Foundation International Award in Science, the William Allan Award from the American Society of Human Genetics and the Richard Lounsbery Award from the National Academy of Sciences.
Follow Bert Vogelstein:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Nickolas Papadopoulos
Founder of Thrive Earlier Detection
Nickolas Papadopoulos is an expert in cancer diagnostics and the development of diagnostic tests. He is internationally known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC). His discovery that mutations in the mismatch repair genes predispose to HNPCC had important ramifications for the understanding of cancers with a very high rate of mutations and led to the development of diagnostic tests for the presymptomatic diagnosis of individuals with HNPCC. Nick part of the interdisciplinary team that was first to sequence all of the protein coding genes and determine genetic alterations and construct expression profiles in multiple tumors of four different common human cancers. Later, he identified novel mutations in chromatin remodeling genes, connecting genetic alterations to epigenetic changes. Currently, Nick is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. Nick is currently professor of oncology and pathology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Follow Nickolas Papadopoulos:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Kenneth Kinzler
Founder of Thrive Earlier Detection
Ken W. Kinzler is a world recognized expert on the molecular and genetic analysis of human cancer. He has been recognized for his role in uncovering the genetic alterations linked to the initiation of colon cancer; development of novel approaches for the molecular analysis of cancer; and more recently, for his role in deciphering the genetic blueprints of many types of cancer. In the late 2000s, Ken and Thrive co-founder Bert Vogelstein, M.D., led a team of scientists who decoded the genomes of many cancers, including breast, colon, pancreatic, brain, ovarian and liver. His work has spawned over 100 patent applications, most focused on the use of genetic approaches to improve the diagnosis and management of patients with cancers and other serious diseases. Ken is currently professor of oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins University and associate director for basic research for the Sidney Kimmel Comprehensive Cancer Center (SKCCC). He is also a member of the National Academy of Sciences, National Academy of Medicine, and National Academy of Inventors and is a fellow of American Association of Cancer Research Academy. Ken is the recipient of numerous awards for his genetic analyses of human cancer, including the inaugural National Brain Tumor Society Founders Award, the 2013 American Association for Cancer Research (AACR) Team Science Award for Pancreatic Cancer Research, the 2014 AACR Team Science Award for Brain Cancer Research and the 2017 AACR Team Science Award for Liquid Biopsies. He has co-authored more than 400 peer-reviewed articles on the molecular analyses of cancer.
Follow Kenneth Kinzler:
About Thrive Earlier Detection: Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Dario Campana
Scientific Founders of Cogent Biosciences
Follow Dario Campana:
About Cogent Biosciences: Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Danny Reinberg
Founder of Constellation Pharmaceuticals
Professor of Biochemistry, New York University School of Medicine Howard Hughes Medical Institute Investigator
Follow Danny Reinberg:
About Constellation Pharmaceuticals, Fulcrum Therapeutics: Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
Yang Shi
Founder of Constellation Pharmaceuticals
Professor of Cell Biology, HMS and Merton Bernfield Professor of Neonatology at Children’s Hospital
Follow Yang Shi:
About Constellation Pharmaceuticals: Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
James Heywood
Co-Founder of AOBiome
James Heywood is the co-founder and CEO at PatientsLikeMe. When his brother Stephen was diagnosed with ALS in 1999, Jamie founded the world’s first non-profit biotech, the ALS Therapy Development Institute. As its CEO for 8 years, Jamie grew ALS TDI to be the world’s largest ALS research program. He completed the first published stem cell transplant in ALS, developed a unique high throughput in vivo drug validation program, collaborated with dozens of companies, and brought 2 drugs to a clinical trial. An engineering graduate of MIT, Jamie’s unique approach to disease research and management has been profiled by Pulitzer Prize-winning author Jonathan Weiner in the biography His Brother’s Keeper, 60 Minutes, The New Yorker, and in the Sundance award-winning documentary So Much So Fast.
Follow James Heywood:
About ALS Therapy Development Institute, AOBiome, Confidential: AOBiome is a life sciences company that focuses on transforming human health.
Maya R. Said
CEO and Co-Founder of Outcomes4Me
Maya Said is the Founder and CEO of Outcomes4Me.
Follow Maya R. Said:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Michael Schrader
Co-Founder & CEO of Vaxess Technologies
Michael Schrader is the CEO and co-founder of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world. The company was the winner of the 2013 MassTLC Innovative Life Science Technology of the Year, 2012 Harvard Business Plan Competition and The 2012 Harvard President’s Challenge for Social Entrepreneurship. Prior to founding Vaxess, Michael worked at Google, Toyota, and Honda where he has earned fifteen patents. He holds a BSME from Purdue University and an MBA from Harvard Business School.
Follow Michael Schrader:
About Harvard University, MassChallenge, Vaxess Technologies: Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
M. Charles Liberman
Founder of Decibel Therapeutics
M. Charles Liberman is the Schuknecht Professor of Otology and Laryngology at the Harvard Medical School and the Director of the Eaton-Peabody Laboratories at the Massachusetts Eye and Ear, one of the largest and best-known research groups devoted to the study of hearing and deafness. The laboratory comprises 27 investigators, with research foci spanning all aspects of the auditory system from sound transmission in the middle ear, through signal transduction in the inner ear and neural processing in the central nervous system. Dr. Liberman received his B.A. in Biology from Harvard College in 1972 and his Ph.D. in Physiology from Harvard Medical School in 1976. He has been on the faculty at Harvard since 1979, has published over 160 papers on a variety of topics in auditory neuroscience and is the recipient of the Award of Merit from the Association for Research in Otolaryngology, the Carhart Award from the American Auditory Society and Bekesy Silver Medal from the Acoustical Society of America. His research interests include 1) coding of acoustic stimuli as neural responses, 2) efferent feedback control of the auditory periphery, 3) mechanisms underlying noise-induced hearing loss, 4) the signaling pathways mediating nerve survival in the inner ear and 5) application of cell- and drug-based therapies to the repair of a damaged inner ear.
Follow M. Charles Liberman:
About Decibel Therapeutics: Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Gabriel Corfas
Founder of Decibel Therapeutics
Follow Gabriel Corfas:
About Decibel Therapeutics, University of Michigan, University of Michigan Medical School: Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Patrick Ohiomoba
Co-Founder and CTO of Marvin
Patrick Ohiomoba is the Co-Founder and CTO at Marvin.
Follow Patrick Ohiomoba:
About Marvin: Marvin is a virtual care platform that provides teletherapy and behavioral health services to healthcare workers.
Anthony Hyman
Co Founder of Dewpoint Therapeutics
Follow Anthony Hyman:
About Dewpoint Therapeutics: Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.
Simon Read
Founder and CEO of Curie Therapeutics
Simon Read is the Founder and CEO Curie Therapeutics.
Follow Simon Read:
About Curie Therapeutics: Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Julie Legault
Executive Director, Founder of Amino Labs
Julie legault is the creative director, founder and ceo of amino labs inc, the company pioneering accessible bioengineering in the home and school. As a designer, julie works to make scientific and technological innovations approachable to the public, crafting experiences and products that invite culture shifts. She holds a master of art from the school of materials at the royal college of art (uk), degrees in both design technology and arts from concordia university (canada), and a masters of science from the mit media lab, massachusetts institute of technology(usa). She has taught at birmingham’s institute of art and design (uk) and worked with multi-nationals (aston martin, nokia, bombay sapphire,audi, etc), , museums, and pop stars like rihanna and imogen heap to develop smart materials, wearable technologies, and interactive art.
Follow Julie Legault:
About Amino Labs: Amino Labs is a biotechnology company that aims to make genetic engineering accessible to everyone.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Allan M. Fox
Co-Founder of Dimension Therapeutics
Allan M. Fox is the founder and a partner of FoxKiser since 1986. He is specialized in identifying and enhancing business opportunities and improving competitive market positions in the pharmaceutical and biotechnology industries. Fox provided his services as the director of Dimension Therapeutics from 2013 to 2015. He has also held the same position at REGENX Biosciences. Fox holds a degree in law, science, and medicine from Yale Law School. He also obtained a juris doctorate and bachelor’s degree from Temple University.
Follow Allan M. Fox:
About Dimension Therapeutics, FoxKiser: Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
George Foot
Co-Founder & Co-CEO of Sixfold Bioscience
George Foot is the Co-Founder & Co-CEO at Sixfold Bioscience.
Follow George Foot:
About Sixfold Bioscience: Sixfold Bioscience develops and researches on biotechnology advances for RNA therapies.
Jane Osbourn
Co-Founder, Chief Scientific Officer & Chief Technology Officer of Alchemab Therapeutics
Jane Osbourn is the chairman at Mogrify.
Follow Jane Osbourn:
About Alchemab Therapeutics: Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Pierre Leurent
Founder & CEO of Voluntis
Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.
Follow Pierre Leurent:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Benjamin Ebert
Founder of Ligon Discovery
Benjamin Ebert is the Founder of Neomorph.
Follow Benjamin Ebert:
About Ligon Discovery, Neomorph: Ligon Discovery identifies drugs in the fields of oncology and coagulation disorders using small molecule microarray screening technology.
Jason Gardner
CEO, President & Co-Founder of Magenta Therapeutics
Jason is CEO, President and Cofounder of Magenta Therapeutics, a biotechnology company created to transform stem cell transplantation. He joined Atlas Venture as an Entrepreneur-in-Residence to create Magenta, working with Third Rock Ventures. He has held leadership roles in pharma and biotech over 18 years, where he most recently established and ran the GSK R&D Satellite in Boston. He also created and led the Regenerative Medicine Discovery Performance Unit, a global team across R&D that established the stem cell gene therapy programs in pharma and ran multiple collaborations. Jason joined GSK in 2005 following eight years in the biotech arena to become a member of the lapatinib clinical team that led to the successful new drug application file for Tykerb in breast cancer in 2007. He then joined the CEEDD, later leading Research and Alliance Management, where new alliances were established with multiple biotech companies. In 2009, he created the Stem Cell DPU to deliver on the therapeutic and platform promise in regenerative medicine. Under his stewardship, the stem cell gene therapy alliance was formed with Fondazione Telethon, one of the biggest biomedical charitable foundations in Italy, and GSK’s Rare Disease Unit, and the team spearheaded GSK’s collaboration with the Harvard Stem Cell Institute. Jason was educated at Cambridge University where he received B.A. and M.A. degrees in Natural Sciences. He completed his Ph.D. at Oxford University and was a Research Fellow in Medicine at Harvard University.
Follow Jason Gardner:
About Magenta Therapeutics: Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Gordon Wishart
Founder and Chief Medical Officer of CHECK4CANCER LTD
Gordon Wishart graduated MB ChB from the University of Edinburgh in 1983 followed by an MD in 1992 for a thesis entitled “Aspects of multidrug resistance in breast cancer”. Gordon Wishart received fellowships from the Royal College of Physicians and Surgeons of Glasgow in 1987 and the Royal College of Surgeons of England in 2001. Following his first consultant appointment in Sussex in 1995, Professor GC Wishart moved to Addenbrooke’s Hospital, Cambridge in 1998 to take up the post of consultant breast & endocrine surgeon with a remit to develop and modernise breast cancer services. Professor Gordon C Wishart was Director of the Cambridge Breast Unit from 2005 to 2010 and was appointed as Visiting Professor of Cancer Surgery at Anglia Ruskin University, Cambridge in December 2008. Gordon Wishart has a national and international reputation in the field of breast cancer and has published widely in the field of breast cancer, including sentinel node biopsy, endocrine surgery and breast cancer. A full list of his publications is listed below and can also be found on the PubMed website by searching for Wishart GC. In some of his research articles he will be listed as GC Wishart. Gordon Wishart was instrumental in raising £2 million to build the Cambridge Breast Cancer Research Unit in 2008, a clinical and laboratory facility to support the clinical research programme. He is the lead or co-investigator on clinical trials that have attracted over £2 million in grant funding. He has recently been an advisor to the Department of Health as part of the cancer waiting times and national cancer survivorship initiatives. Gordon Wishart’s main areas of research interest include factors that lead to variation in breast cancer survival and the effect of screen-detection on survival. He recently led a team of clinicians and scientists to produce a new model, Predict, that estimates the survival and treatment benefits following surgery for invasive breast cancer (www.predict.nhs.uk). The second version of Predict, launched in July 2011, is the first clinical prognostication model for breast cancer to include HER2 and the benefit of trastuzumab (Herceptin).
Follow Gordon Wishart:
About Anglia Ruskin University, CHECK4CANCER LTD, CHECK4CANCER LTD: Check4Cancer offers corporate health screening for skin cancer, lung cancer, breast cancer and prostate cancer
Anita Lee
Founder of IVF Insight
Follow Anita Lee:
About IVF Insight: IVF Insight creates a platform of trusted in-vitro fertilization locations.
Zena Sfeir Gehchan
Co-Founder of Sohati
Entrepreneurial spirited, passionately curious about health management and innovation, selected among the “50 entrepreneurs outside the US you need to know”. Enthusiastic about sharing value and creating connections with people and ideas; Her experience helped her gain extensive knowledge in leading and executing ideas with culturally diverse teams in the digital space. The world of marketing and innovation with social impact is where her interest lies.
Follow Zena Sfeir Gehchan:
About Sohati: Sohati is an e-health platform provides information on the health and medical field.
Oriane Chausiaux
Founder Director – CSO, Serial Entrepreneur of Heartfelt Technologies
Follow Oriane Chausiaux:
About Heartfelt Technologies: Heartfelt Technologies are developing the only home-based heart failure monitor that does not require patient interaction or compliance.
Erik Gatenholm
Co-Founder & CEO of Cellink
Follow Erik Gatenholm:
About BICO, Cellink: Cellink is a biotechnology company optimized bench-top bioprinter for the ultimate bioprinting of human tissues.
James Gibbons
Co-Founder & CEO of SBR Health
James F. Gibbons is a Co-Founder and Chairman of the Board of Directors at SBR Health since 2010. Jim joined the Stanford faculty in 1957, was appointed Professor of Electrical Engineering in 1964, and dean of the School of Engineering in 1984. In 1983 Jim was named Reid Weaver Dennis Professor of Electrical Engineering and in 1984 the Frederick Emmons Terman Dean of the School of Engineering. Jim served as Dean from September 1984 to June 1996. Jim has been an advisor and board member of public companies Cisco Systems, El Paso Energy, Lockheed Martin, Raychem. Jim’s research accomplishments are in the area of semiconductor device analysis, process physics technology and solar energy. Jim has written or co-written several books and nearly 300 papers. Gibbons was named Special Counsel to Stanford University President and Provost for Industry Relations in 1966. Jim is credited with developing the Tutored Video Instruction Technique, a model for education of engineers, with colleagues from Stanford in 1972. In recent years, Jim applied that model to improve productivity and quality in children’s education, particularly for children of migrant farm workers and at-risk teens. Jim has received many awards and was elected a member of the National Academy of Engineering, the National Academy of Sciences and the American Academy or Arts and Sciences. In 1997, Jim was inducted into the Santa Clara County Business Hall of Fame and was one of three chosen for the Silicon Valley Engineering Hall of Fame. Jim received a B.S. (1953) degree from Northwestern University and a Ph.D. (1956) from Stanford University.
Follow James Gibbons:
About SBR Health, Stanford University: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Christopher Herot
CEO & Co-Founder of SBR Health
Chris Herot is the CEO and co-founder of SBR Health. Prior to launching SBR in 2010, Chris was Chief Product Officer at VSee Lab, a provider of high quality, low bandwidth and low cost videoconferencing solutions to enterprises and governments. Chris has been a successful business and technology leader in several high growth companies, and directed the advanced technology group for several years at Lotus Development (now IBM) where he was responsible for video, mobile and real-time communications solutions. Chris received his BS and MS degrees from the Massachusetts Institute of Technology where he was on the faculty of the group that became the MIT Media Laboratory.
Follow Christopher Herot:
About SBR Health: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Anurag Agarwal
Founder of The Cambridge Stethoscope Company
Follow Anurag Agarwal:
About The Cambridge Stethoscope Company: The Cambridge Stethoscope Company is developing the world’s first intelligent stethoscope that is capable of automated diagnosis.
Laurence Rahme
Scientific Founder of Spero Therapeutics
Laurence RahmeLaurence Rahme, MS, PhD, is the Scientific Founder of Spero Therapeutics in Cambridge.
Follow Laurence Rahme:
About Harvard Medical School, Spero Therapeutics: Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
Salvatore Mascia
Founder & President of CONTINUUS Pharmaceuticals
Salvatore Mascia is the Founder & CEO of CONTINUUS Pharmaceuticals. He was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the first end-to-end continuous manufacturing process for pharmaceuticals. At the end of the project, he was presented with the “Leadership Award” that recognized his leadership role at the Center. Salvatore has gained experience in strategic management and fund raising in addition to leadership skills via various roles of responsibility within the entrepreneurial ecosystem. Among those, he co-founded “Professionisti Italiani a Boston” in 2009, and served as President of the “Cambridge University Technology and Enterprise Club” in 2006/07. He also ran a pharmacy business for 2 years. Salvatore completed a post-doc at MIT in Chemical Engineering and holds a PhD in Chemical Engineering from the University of Cambridge, UK and a BS and MS in Pharmacy (summa cum laude) from University of Perugia, Italy.
Follow Salvatore Mascia:
About CONTINUUS Pharmaceuticals: Continuus Pharmaceuticals designs, builds, and runs manufacturing processes for pharmaceutical and generic clients.
David Woodley
Co-Founder of Lotus Tissue Repair
Follow David Woodley:
About Lotus Tissue Repair: Lotus Tissue Repair develops an accelerating chronic wound healing technology for the treatment dermatologic conditions such as foot ulcers.
Sudhir Borgonha
Co-Founder and Chief Medical Officer of ten3T
Follow Sudhir Borgonha:
About ten3T: ten3T is a medical grade wearable device startup.
William M. Pardridge
Founder & CSO of ArmaGen Technologies
Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood-brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing the antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 450 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.
Follow William M. Pardridge:
About ArmaGen Technologies: ArmaGen is focused on developing technologies for siRNA delivery across the blood-brain barrier.
Danielle Zurovcik
Founder & CEO of WiCare
Danielle Zurovcik is the founder and CEO of WiCare.
Follow Danielle Zurovcik:
About WiCare: WiCare develops innovative medical devices that are clinically effective and affordable worldwide.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Goutam Reddy
Founder, CEO of Abiogenix
‘Greddy’ devised the overall architecture of the uBox system, including designing the electronics and firmware of the uBox and uKey. Greddy holds past EE design experience from working for MolySym as well as sensing and robotics from the Biomechatronics Group at the MIT Media Lab. He also has relevant developing-world experience from Developing World Prosthetics, a non-profit he co-founded to improve low-cost rehabilitation devices. Greddy received a Master’s in Electrical Engineering and Computer Science (EECS), as well as B.S. degrees in Mathematics and EECS from MIT.
Follow Goutam Reddy:
About Abiogenix: Abiogenix helps patients improve their medication adherence, which in turn reduces healthcare costs for providers and payers and increases
Christopher Stanley
Co-Founder of Circular1 Health
Follow Christopher Stanley:
About Circular1 Health: Circular1 Health provides data testing services to operational and close contact companies.
Christopher Loose
Co-Founder and Chief Technology Officer of Semprus BioSciences
Follow Christopher Loose:
About Semprus BioSciences: Semprus BioSciences is a venture-backed biomedical company developing medical devices implementing the Semprus technology.
Matthew Young
CTO & Founder of Oval Medical Technologies Ltd.
Follow Matthew Young:
About Oval Medical Technologies Ltd.: Oval Medical Technologies Limited is a specialty pharmaceutical device company
Stewart Newlove
Founder of Antibodies.com
Stewart Newlove is the Founder of Antibodies.
Follow Stewart Newlove:
About Antibodies.com: Antibodies.com is a leading supplier of protein research tools. Discover more from our range of distinct antibodies, proteins, and assays.
Dixon Magister
Co-Founder of PillDrops
Follow Dixon Magister:
About PillDrops: Making the pill taking process safer and easier.
Michael Harradon
Co-Founder of High Q Imaging
Follow Michael Harradon:
About High Q Imaging: HQI builds a low-cost, portable MRI that aims to substantially reduce the price of medical imaging through newly developed technology.
David Liu
Founder of Ensemble Discovery
Follow David Liu:
About Ensemble Discovery: Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.
